Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.66 -1.93%

-$0.64 today

Market cap
$2.22B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.28M

Average 0.31M

Returns on capital

Pharvaris N.V. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-64.8%

avg -42.1%

ROIC

-62.4%

avg -43.4%

ROA

-58.3%

avg -38.6%

Analysis

ROA is currently the strongest return metric at -58.3% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Berndt Axel Edvard Modig

Co-Founder, Chief Executive Officer & Executive DirectorEUR 1.54M67——

Anne Lesage

Chief Early Development Officer—6573.97K0.11%

Maggie Beller

VP & Head of Corporate and Investor Communications————

Maryann Cimino

Director of Corporate Relations————

Wim Souverijns

Chief Commercial Officer—5539.02K0.06%

Anna Nijdam

Head of Strategic Finance & Principal Accounting Officer—4546.27K0.07%

Peng Lu

President—48109.81K0.16%

Annick Deschoolmeester

Chief Human Resources Officer—5345.00K0.06%

David W. Nassif

Chief Financial Officer, Chief Legal Officer & Corporate Secretary—72113.80K0.16%

Stefan Abele

Chief Technology Operations Officer—56——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

70

$32.91M

Net Transaction Value

−$32.91M

Net selling

Most Active

Lesage Anne

18 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 23, 26

Monges Viviane

Direct

Sell$395.5K
Sep 22, 26

Schikan Johannes Gerardus Christiaan Petrus

Direct

Sell$29K
Sep 21, 26

Nassif David W.

Direct

Sell$218.8K
Sep 17, 26

Bjork Elisabeth

Direct

Sell$2M
Sep 17, 26

Glassman Robert

Direct

Sell$558.8K
Sep 17, 26

Lesage Anne

Indirect

Sell$765.5K
Sep 17, 26

Schikan Johannes Gerardus Christiaan Petrus

Direct

Sell$7M
Sep 17, 26

Lu Peng

Direct

Sell$3.5M
Sep 15, 26

Abele Stefan Andreas

Direct

Sell$1.7M
Sep 15, 26

Abele Stefan Andreas

Direct

Sell$54.9K

1–10 of 70

Summary

Insiders reported 0 buys worth $0.00 and 70 sells worth $32.91M over the last 12 months. That adds up to net selling of $32.91M. Lesage Anne was the most active insider with 18 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A0 analysts
Net IncomeN/AN/AN/A
N/A0 analysts
EBITN/AN/AN/A
N/A0 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Pharvaris N.V. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PHVS's management, answered from reported figures.

Who manages PHVS?

Pharvaris N.V. (PHVS) lists 10 active executives. The top listed executive is Anne Lesage, Chief Early Development Officer.

Are PHVS insiders buying or selling?

Recent insider activity shows net selling of $43.30M.